BioFact Genomic DNA Prep Kit (Yeast)
- Known as:
- BioFact Genomic Desoxyribonucleic acid Prep Kit (Yeast)
- Catalog number:
- bf0031
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Biofact
- Gene target:
- BioFact Genomic DNA Prep Kit (Yeast)
Related genes to: BioFact Genomic DNA Prep Kit (Yeast)
- Gene:
- PREP NIH gene
- Name:
- prolyl endopeptidase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-03-12
- Date modifiied:
- 2016-10-05
Related products to: BioFact Genomic DNA Prep Kit (Yeast)
Related articles to: BioFact Genomic DNA Prep Kit (Yeast)
- Interventions are needed to address the lack of pre-exposure prophylaxis (PrEP) awareness and mitigate barriers related to PrEP use. One such intervention modality is social media, as PrEP awareness and communication on issues, such as access and cost, are easily addressed via clear social media messages on platforms for PrEP-eligible people, and especially young people, who use social media more frequently. - Source: PubMed
Publication date: 2026/09/30
Martinez Lourdes SCrocker NicoleAkkone SharanyaHariprasad ShravaniHoughton RebeccaWalsh-Buhi Eric R - The treatment and prevention of HIV have undergone significant transformations in the 16 years since the last major review of HIV therapeutics published in ASM's (A. M. N. Tsibris and M. S. Hirsch, J Virol 84:5458-5464, 2010, https://doi.org/10.1128/jvi.02524-09). First-generation antiretroviral medications, many now discontinued, have been replaced by integrase strand transfer inhibitor-based regimens that offer superior efficacy, higher genetic barriers to resistance, and the convenience of a single-tablet fixed-dose combination. Dolutegravir and bictegravir are now the anchors of most first-line therapies worldwide, and two-drug and nucleoside reverse transcriptase inhibitor (NRTI)-sparing strategies have emerged, allowing for simplification of treatment of patients who had been previously on complex regimens. The most consequential recent advance, though, has been the introduction of long-acting injectable medications, including cabotegravir-rilpivirine for treatment, standalone cabotegravir for pre-exposure prophylaxis (PrEP), and lenacapavir, a first-in-class capsid inhibitor for both treatment and PrEP. For people with multidrug-resistant HIV, new agents including fostemsavir, ibalizumab, and lenacapavir have made virologic suppression achievable in virtually all heavily treatment-experienced patients. An investigational and emerging pipeline that includes third-generation integrase inhibitors, nucleoside reverse transcriptase translocation inhibitors, maturation inhibitors, and broadly neutralizing antibodies promises further expansion of HIV therapeutic options. These advances, however, come with potential challenges, including emergent resistance to long-acting agents, metabolic consequences of lifelong therapy in an aging population, persistent inequities in global access to newer agents, and often insufficient safety data in pregnancy and breastfeeding. This review provides a clinical assessment of the current antiretroviral options, from legacy agents to investigational therapies, with attention to the resistance, implementation, and special population considerations that will shape HIV practice in the future. - Source: PubMed
Publication date: 2026/09/30
Bacic Lima DaniloLi YijiaCherabie Joseph NSaldana Carlos S - Recipients of HIV pre-exposure prophylaxis (PrEP) experience higher rates of gonorrhea and chlamydia diagnoses than non-recipients. However, it is unclear if these observations reflect a causal relationship between PrEP initiation and acquisition of sexually transmitted infections (i.e., behavioral "risk compensation") or a diagnostic bias related to PrEP recipients screening more frequently than non-recipients. - Source: PubMed
Publication date: 2026/09/30
Parker Anna MJenness Samuel MSinger Benjamin JChang Jennifer JBruxvoort Katia JLewnard Joseph A - Disaster response requires a diverse set of skills, yet there is no universally agreed definition of the specific competences needed. Therefore, this study aimed to explore how disaster responders acquire competence. - Source: PubMed
Publication date: 2026/09/30
Westman AnjaKurland LisaHugelius Karin - The use of antiretroviral (ARV) medications for HIV treatment and prevention is a potential blood safety concern. HIV screening algorithms rely on the predictable appearance of viral RNA, p24 antigen, and anti-HIV antibodies during acute and early infection. However, exposure to ARVs can alter these biomarker dynamics and potentially compromise HIV detection. Evidence indicates that early initiation of antiretroviral therapy (ART) can suppress viremia, leading to incomplete seroconversion, reduced serologic reactivity, and seroreversion. HIV acquisition may also occur in individuals receiving pre- or postexposure prophylaxis (PrEP/PEP), resulting in delayed or altered progression of virologic and serologic markers. Long-acting injectable PrEP formulations, particularly cabotegravir, have been associated with prolonged delays in HIV diagnosis, Undisclosed ART among donors who have HIV infection has been reported in studies from South Africa, Brazil, and the USA. Undisclosed PrEP use has been reported in Canada, the Netherlands, the UK, and the USA. This has the potential to lead to undetected HIV infections in blood donors. Broader availability of ARVs and implementation of HIV treatment and prevention programs increase the relevance of this issue for blood safety. A limitation for defining ARV-associated HIV transfusion transmission risk is the availability of high-quality evidence on the likelihood of donations with altered biomarkers of infection. A framework for risk assessment in the context of sparse data is described. Additional evidence and evaluation of known or potential undisclosed ART, PrEP or PEP use in donors is required before more precise risk estimates are possible. - Source: PubMed
Publication date: 2026/09/08
Buccheri RenataGrebe EduardCuster Brian